Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease
January 17 2018 - 8:00AM
Lyfebulb, a chronic disease-focused, patient-empowerment platform
that connects patients, industry and investors to support
user-driven innovation, is partnering with UnitedHealth Group
(NYSE:UNH) to launch an innovation challenge featuring new
businesses and products aimed at treating inflammatory bowel
disease (IBD).
According to the Centers of Disease Control and
Prevention, up to 1.3 million people in the United States are
affected by IBD, which includes Crohn’s disease (CD) and ulcerative
colitis (UC). Lyfebulb and UnitedHealth Group will help raise
awareness for the conditions and stimulate user-driven innovation.
By linking entrepreneurs with representatives from UnitedHealth
Group and Lyfebulb, the partnership will spotlight the
entrepreneurs’ efforts and ideas, and provide professional
discussion, direction and inspiration.
The innovation challenge, to take place in the
spring and summer of 2018, will be open to entrepreneurs living
with IBD, or who have family members living with IBD, who have
founded a company to develop an innovative idea for better
management of IBD using pharmaceuticals, biotechnology, medical
devices or consumer products. Eligibility criteria and
official rules will be announced by Lyfebulb in April. UnitedHealth
Group will host an innovation event in July for 10 finalists. A
panel of judges will award cash prizes to three winners, to be used
for their company’s further development of the winning
innovations.
“Patients living with chronic disease and
caregivers caring for someone with chronic disease understand the
many challenges they face and are often in the best position to
offer tangible solutions,” said Deneen Vojta, M.D., executive vice
president, Research & Development, UnitedHealth Group.
“UnitedHealth Group’s partnership with Lyfebulb will help place the
patient at the center of early-stage innovation, thus providing us
a unique opportunity to learn from and be inspired by
patient-entrepreneurs.”
“This partnership with UnitedHealth Group in IBD
means a tremendous amount to Lyfebulb in our efforts to enhance
patient-driven innovation,” said Dr. Karin Hehenberger, CEO and
Founder of Lyfebulb. “Continuing to build on the concept of patient
entrepreneurs and partnering with leaders across health care are
key components to fulfilling our mission to improve the quality of
life of people living with chronic disease.”
Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD, CEO Lyfebulb, phone: 917-575-0210
email: karin@lyfebulb.com
About LyfebulbLyfebulb is a
chronic disease focused, patient empowerment platform that connects
patients, Industry (manufacturers and payers) and investors to
support user-driven innovation. Lyfebulb promotes a healthy,
take-charge lifestyle for those affected by chronic disease.
Grounded with its strong foundation in Diabetes, the company has
expanded disease states covered into Cancer and IBD.
See www.lyfebulb.com, Facebook, Twitter,
Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About UnitedHealth
GroupUnitedHealth Group (NYSE:UNH) is a diversified health
and well-being company dedicated to helping people live healthier
lives and helping make the health system work better for everyone.
UnitedHealth Group offers a broad spectrum of products and services
through two distinct platforms: UnitedHealthcare, which provides
health care coverage and benefits services; and Optum, which
provides information and technology-enabled health services. For
more information, visit UnitedHealth Group at
www.unitedhealthgroup.com or follow @UnitedHealthGrp on
Twitter.
Press Contact for UnitedHealth Group:Jim
Merwin, Senior Director, ERD, phone: 952-936-6070, to email:
james_merwin@uhg.com
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Mar 2024 to Apr 2024
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Apr 2023 to Apr 2024